Get the Daily Brief
Latest Biotech News
Sino Biopharma Acquires LaNova to Expand Antibody Pipeline in China
Sino Biopharmaceutical announced acquisition of the remaining 95% stake in LaNova Medicines for up to $951 million, consolidating its antibody-drug conjugate and bispecific antibody assets....
AstraZeneca’s Baxdrostat Shows Promise in Treatment-Resistant Hypertension
AstraZeneca’s aldosterone synthase inhibitor, Baxdrostat, succeeded in its Phase III BaxHTN trial, meeting primary and secondary endpoints in patients with uncontrolled or treatment-resistant...
Takeda Advances Narcolepsy Treatment with OX2R-Selective Agonist
Takeda announced positive Phase III results for oveporexton (TAK-861), an oral orexin receptor 2 (OX2R) selective agonist for narcolepsy type 1, meeting all key endpoints related to wakefulness...
FDA Rejects Ultragenyx Gene Therapy Over Manufacturing Issues
Ultragenyx Pharmaceutical’s gene therapy candidate for Sanfilippo syndrome type A, UX111, received a complete response letter from the FDA citing manufacturing (CMC) concerns unrelated to product...
Global Neurodegeneration Proteomics Consortium Uncovers Biomarkers
The Global Neurodegeneration Proteomics Consortium (GNPC) released one of the world’s largest dementia-related proteomic datasets, comprising approximately 250 million unique protein measurements...
Novel Optogenetic Drug Screening Platform Reveals ISR Modulators
Integrated Biosciences unveiled an optogenetics-based screening platform allowing precise temporal and spatial modulation of cell signaling pathways. Applying it to the integrated stress response...
HIV Prevention Advances: FDA Approvals and Late-Stage Trials
Gilead’s injectable HIV prevention drug Yeztugo (lenacapavir) received FDA approval as the first twice-yearly PrEP medication, showing near-complete protection in large clinical trials across...
Expansion of Waters Corp. Clinical Footprint via $17.5B BD Acquisition
Waters Corporation announced its $17.5 billion acquisition of Becton Dickinson’s Biosciences and Diagnostics Solutions business, marking the largest life sciences deal of 2025. The combined entity...
FDA’s roadmap to replace animal testing accelerates drug evaluation
In April 2025, the FDA unveiled an ambitious plan to phase out animal testing in drug development within three to five years, aiming to adopt more human-relevant methods such as AI-driven...
Breakthrough trispecific antibody shows promise in multiple myeloma
AbbVie licensed ISB 2001, a novel trispecific T-cell engager targeting BCMA, CD38, and CD3, from Ichnos Glenmark Innovation for potentially over $1.9 billion. In a Phase I trial reported at ASCO...
Global proteomics consortium reveals neurodegenerative disease biomarkers
The Global Neurodegeneration Proteomics Consortium (GNPC) published extensive analyses from the largest proteomic dataset to date, encompassing 250 million protein measurements from over 35,000...
Hengrui/Kailera obesity drug delivers significant weight loss in Phase III China trial
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced positive Phase III results from China for HRS9531, a once-weekly injectable GLP-1/GIP receptor dual agonist. The trial showed...
Waters to acquire BD’s biosciences and diagnostics unit for $17.5 billion
Waters Corporation announced a $17.5 billion acquisition of Becton Dickinson’s Biosciences and Diagnostics Solutions business, expanding Waters into molecular testing and clinical diagnostics. The...
AI-powered open-source RT-LAMP assay offers affordable pathogen detection
A joint research team from Austria and Ghana developed an open-source, freeze-dried reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for pathogen detection optimized...
Takeda’s oral orexin receptor agonist wins Phase III narcolepsy trials
Takeda Pharmaceutical’s oral orexin receptor 2 (OX2R)-selective agonist, oveporexton (TAK-861), achieved all primary and secondary endpoints in two registrational Phase III trials for narcolepsy...
Gilead’s twice-yearly HIV prevention shot gains FDA approval
The FDA approved Gilead Sciences’ Yeztugo (lenacapavir), the first-in-class injectable antiretroviral drug offering nearly complete protection against HIV-1 infection with only two doses per year....
Sino Biopharm acquires majority stake in China’s LaNova Medicines for up to $951 million
Sino Biopharmaceutical announced an agreement to acquire the remaining approximately 95% stake in LaNova Medicines, a Shanghai-based cancer biotech known for PD-1xVEGF bispecific antibodies and...
Novel approach to combat MRSA via bacterial calcification unfolds
A recent Nature Biotechnology publication details a strategy to eradicate methicillin-resistant Staphylococcus aureus (MRSA) infections by inducing calcification on bacterial surfaces, thereby...
Big pharma bets reshape drug discovery landscape
In June 2025, major pharmaceutical companies executed high-profile transactions and collaborations to expand their drug discovery capabilities. Sanofi acquired Blueprint Medicines for $9.1...
Waters to acquire BD biosciences and diagnostics for $17.5B
Waters Corporation announced a $17.5 billion acquisition of Becton Dickinson's Biosciences and Diagnostics Solutions division, aiming to significantly expand its presence in clinical diagnostics...